Filing Flows › 8-K events › Cullen/Frost Bankers
Cullen/Frost Bankers: notice of delisting or failure to meet a listing standard
Form 8-K filed Oct 29, 2026 · items 3.01, 7.01
What the filing says
On October 29, 2026, Cullen/Frost Bankers, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors (the “Board”), notified the New York Stock Exchange (“NYSE”) of its intention to voluntarily withdraw the listing of: (i) its common stock, par value $0.01 per share (the “Common Stock”) and (ii
Read the filing on SEC EDGAR →
What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Every item ranked →
What this kind of filing means
Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.
Cullen/Frost Bankers at a glance
Cullen/Frost Bankers, Q3 2026: revenue $604M (+6% year over year), operating margin 35.5%. The chart follows the revenue to costs, profit and cash.
Cullen/Frost Bankers: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent delisting notices
- Barfresh Food Group Nov 6, 2026
- Fifth Era Acquisition Corp I Nov 6, 2026
- Tempest Therapeutics Nov 6, 2026
- Roku Nov 6, 2026
- Bowman Consulting Group Nov 6, 2026
- Knightscope Nov 6, 2026
- Curis Nov 6, 2026
- Intrusion Nov 5, 2026
- Karyopharm Therapeutics Nov 5, 2026
- Cognition Therapeutics Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.